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The F2RL3 gene encoding protease activated receptor 4 (PAR4) contains a single
nucleotide variant, rs773902, that is functional. The resulting PAR4 variants, Thr120,
and Ala120, are known to differently affect platelet reactivity to thrombin. Significant
population differences in the frequency of the allele indicate it may be an important
determinant in the ethnic differences that exist in thrombosis and hemostasis, and for
patient outcomes to PAR antagonist anti-platelet therapies. Here we determined the
frequency of rs773902 in an Indigenous Australian group comprising 467 individuals
from the Tiwi Islands. These people experience high rates of renal disease that may
be related to platelet and PAR4 function and are potential recipients of PAR-antagonist
treatments. The rs773902 minor allele frequency (Thr120) in the Tiwi Islanders was
0.32, which is similar to European and Asian groups and substantially lower than
Melanesians and some African groups. Logistic regression and allele distortion testing
revealed no significant associations between the variant and several markers of renal
function, as well as blood glucose and blood pressure. These findings suggest that
rs773902 is not an important determinant for renal disease in this Indigenous Australian
group. However, the relationships between rs773902 genotype and platelet and drug
responsiveness in the Tiwi, and the allele frequency in other Indigenous Australian
groups should be evaluated.
Keywords: protease activated receptor 4, rs773902, renal disease, Australian Aboriginal and Torres Strait
Islanders, indigenous genetics
INTRODUCTION
Platelet activation by thrombin during hemostasis and thrombosis is mediated through two
therapeutically tractable protease-activated receptors, PAR1 and PAR4. The gene encoding PAR4
(F2RL3) contains a functionally important single nucleotide polymorphism (rs773902) expressing
either an Ala120 or Thr120 variant receptor. The Thr120 variant is associated with higher
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aggregation and Ca2+ flux induced by PAR4 agonists in
isolated platelets (Edelstein et al., 2014; Whitley et al., 2018),
and greater ex vivo thrombosis formation (Tourdot et al.,
2018). The allele frequencies for this variant differ according
to ethnicity, with the Thr120 variant relatively common in
some African populations (up to 68%) and less common
in Asians and Europeans (19–29%; Edelstein et al., 2014;
Heenkenda et al., 2018). Previous studies comparing PAR4-
dependent platelet functions in African and “white” Americans
indicated distinct differences (Edelstein et al., 2013; Tourdot
et al., 2014), which in other studies have been directly associated
with Ala120/Thr120 variant status (Edelstein et al., 2014).
The variant may also be clinically important. One study has
shown a greater risk of thrombosis amongst carriers of the
Thr120 in a general American population (Whitley et al.,
2018). In addition, the relative benefits and risks of using the
PAR1 antagonist vorapaxar may vary according to the PAR4
sequence variant, with a suggestion of lower bleeding rates in
Thr120-expressing individuals treated with vorapaxar than in
Ala120-expressing individuals (Tricoci et al., 2018). Furthermore,
PAR4 antagonists are in clinical development (French and
Hamilton, 2017; Wong et al., 2017) and the impact of the
rs773902 PAR4 SNP on the efficacy and safety of these agents
remains unexplored.
Indigenous Australians, who represent a distinct population
with ancestral and genetic histories that predate all cultures
outside of Africa, suffer very high burdens of cardiovascular
disease, stroke, diabetes, and chronic kidney disease (CKD;
Australian Institute of Health and Welfare, 2016). For example,
diabetes deaths in Indigenous Australians are increased 15-
fold, cardiovascular deaths by 3–6 fold (Hoy, 1996), and rates
of treated end-stage renal disease are 20 times more than in
non-Indigenous Australians (Spencer et al., 1998). Studies in
these people have also reported familial aggregation amongst
cases of CKD (Van Buynder et al., 1993), and significant
genetic heritability and genetic associations with markers of
renal function (Duffy et al., 2016; Thomson et al., 2019). Both
platelets and PAR4 have been implicated in kidney function
and CKD pathogenesis (Lambert, 2016; Madhusudhan et al.,
2016; Palygin et al., 2016), and renal disease patients are
prone to bleeding and thrombotic events (Saheb Sharif-Askari
et al., 2017). However, the allele frequencies of rs773902 have
not been investigated in Indigenous Australians. Therefore, we
determined the genotype and allele frequencies of rs773902 in
an Indigenous Australian group native to The Tiwi Islands
and analyzed the associations between this variant and markers
of renal disease.
METHODS
Study Participants
The study participants all lived on The Tiwi Islands, located
off the northern coast of Australia in the Arafura Sea. Tiwi
Islanders exhibit a distinct genetic ancestry compared to other
ethnicities (Thomson et al., 2019), and are considered most
closely related to mainland Indigenous Australians (Tiwi Land
Council, 2018). The current total population is approximately
2,500 individuals (ABS, 2016). All the participants were self-
identifying Tiwi Islanders. They were recruited as clinic
outpatients and consented to collection of blood and urine
samples, primarily for characterization of renal function and
DNA for genetic studies. The numbers of participants, their
age ranges and the respective clinical measures used in the
study are shown in Table 1. None of the participants were
experiencing renal failure or receiving renal replacement therapy
at the time the study was performed. A previous analysis of
a separate cohort of self-identifying Tiwi Islanders (n = 73
individuals) indicated low admixture with other populations,
including Europeans (Thomson et al., 2019). The study
received the full support of The Tiwi Island Land Council
and was approved by the human research ethics committees
of The Northern Territory Department of Health (2012–
1767), The Australian National University (2014–663), The
University of Queensland (2012001146), and The University of
Tasmania (H0012832).
Genotyping and Allele Frequency
Analysis
A total of 467 participants were successfully genotyped for the
rs773902 allele. Genotyping was performed on 2.5 ng of genomic
DNA prepared from blood samples using a TaqMan assay and
7900HT Fast Real-Time PCR System (Applied Biosystems), and
standard protocols. A subset of randomly chosen samples (n = 70)
subjected to replicate genotyping were in 100% agreement.
Chi-square test for genotype frequency distortions from Hardy
Weinberg equilibrium were performed using the WPcalc online
tool (Wow-Company).
Clinical Measures
Blood and urine specimens were non-fasting and collected
without regard for time of day. Serum was separated immediately
after clotting, within 20 min in all cases. All specimens were
then refrigerated until transfer to the pathology laboratory
by air, within 24 h. Albumin (mass) and creatinine (molar)
concentrations were analyzed in the spot urine sample and
an albumin/creatinine ratio (ACR) calculated (g/mol). The
estimated glomerular filtration rate (eGFR, mL/min/1.73 m2)
was determined from serum creatinine levels using the MDRD
Study equation (Levey et al., 1999). Blood glucose levels
were determined using standard diagnostic laboratory assay.
Blood and leukocyte positive urine samples were identified
using urine test strips (Bayer Multistix 10 SG Reagent
Urinalysis Test Strips), defined as small, moderate or large,
and ≥1+, respectively. Systolic and diastolic blood pressure
(BP) were measured by a single observer using a mercury
sphygmomanometer. The median and range of the ACR, systolic
and diastolic BP measures amongst the study participants are
provided in Table 1.
Association Studies
Logistic regression was used to estimate the odds ratio
between disease markers and the rs773902 Thr120 allele
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TABLE 1 | Sample characteristics.
Tiwi group Sex Age (year) ACR (g/mol) Systolic BP (mmHg) Diastolic BP (mmHg)
median (range) median (range) median (range) median (range)
All samples 228F, 239M 39 (17–75) 2.3 (0.1–1755)* 113 (71–187)** 74 (48–124)**
CKD unaffected 30F, 30M 37 (30–58) 0.5 (0.1–0.9) 121 (71–187) 77 (51–115)
CKD affected 30F, 30M 43 (19–60) 92.2 (30.2–1755) 107 (85–134) 71 (56–91)
*Data calculated from 455 individuals. **Data calculated from 466 individuals.
using a dose dependent model, and adjustments for age and
sex. The markers used were micro- and macroalbuminuria
(ACR > 3.5 g/mol and ACR > 30 g/mol; available for 455
participants), eGFR < 90 mL/min/1.73 m2 (467 participants),
blood positive urine (dipstick result: large, moderate and small;
454 participants), leukocyte positive urine (dipstick result: ≥1+;
454 participants), hypertension (systolic blood BP > 140 and
diastolic BP > 90; 466 participants), and random blood glucose
(>12.5 mmol/L; 460 participants). The association between renal
disease and the rs773902 Thr120 allele was also examined with a
logistic regression model using a subset of 60 CKD affected and 60
unaffected individuals (Table 1). The 60 CKD affected individuals
were the youngest 30 males and 30 females of the cohort with
ACR ≥ 34 g/mol and any eGFR value. The 60 unaffected
individuals were the oldest 30 males and 30 females of the
cohort with ACR ≤ 3.4 g/mol and eGFR ≥ 90 mL/min/1.73 m2.
These groupings were assigned in consultation with renal
physician Prof. Matthew Jose, University of Tasmania. Selection
according to age was important because of the high frequency of
early-onset renal disease in the Tiwi Islander population (Hoy
et al., 1998), and was applied to minimize inclusion of healthy
younger aged individuals in the unaffected group (who may
go to develop CKD at a later age) and maximize inclusion of
those with early-onset disease in the affected group. The age
distributions of each group are presented in the Supplementary
Figure S1. Linear regression modeling was used to examine
the relationship between the rs773902 Thr120 allele and the
response variables, ACR, systolic and diastolic BP. The response
variable was log transformed for all models and the beta
coefficients were exponentiated to provide response ratios. All
models were adjusted for age and sex, and p-value thresholds
of significance were adjusted for multiple testing using the
Bonferroni method.
RESULTS AND DISCUSSION
The allele frequencies for rs773902 determined for the
entire cohort satisfied Hardy-Weinberg equilibrium and
the minor allele frequency (MAF), encoding Thr120, was
0.32 (Table 2). Logistic regression analyses indicated no
significant relationships between the Thr120 allele and indicators
of abnormal renal function, including microalbuminuria,
macroalbuminuria, eGFR < 90 mL/min/1.73 m2, and blood-
positive and leukocyte-positive urine samples, or hypertension
and random blood glucose concentration. A separate analysis
of the allele frequencies in individuals categorized as CKD
affected versus unaffected (n = 60/60) also revealed no
significant relationship (Table 3). Analyses using linear
regression modeling likewise did not detect any significant
associations with ACR or BP within the whole study cohort
(Table 4). The small sample sizes in our study may be a limiting
factor for detecting statistically significant differences; by
comparison, the seminal study reporting significant associations
between rs773902 and stroke risk included more than 6000
individuals (Whitley et al., 2018). Due to an absence of
data in our cohort, it was not possible to directly test if
cardiovascular disease or thrombosis were associated with
rs773902.
The MAF for rs773902 measured in the Tiwi Islanders
(0.32) was slightly higher than the 0.19–0.29 range observed
in various Asian and European groups, but substantially lower
than the 0.57–0.63 range reported in some African groups
[(Edelstein et al., 2014; Heenkenda et al., 2018); ExAc and
gnomAD data sets]. Notably, the Tiwi Islander frequency was
also lower than Melanesian and Papua New Guinean frequencies
(0.55, Human Genome Diversity Project data set), who are
considered to have a close genetic relationship to Indigenous
Australians (McEvoy et al., 2010) – although it should also be
noted the Melanesian allele data are from only 35 individuals.
The method of participant recruitment for this study was
not randomized across the population, however, the relatively
large sample size (representing approximately 20% of the entire
Tiwi Island population) and the similarities in disease burdens
to other community-wide based surveys of the Tiwi (Hoy
et al., 1998; Hoy et al., 2017) indicate the rs773902 allele
frequencies reported here are an accurate reflection of the Tiwi
Islander people.
The high burden of diseases related to platelet function
in Indigenous Australians and the concomitant use of anti-
platelet therapies should motivate further investigation to
understand the functional effects of the variant in these
populations. It will also be of interest to determine if
TABLE 2 | rs773902 genotype and allele frequencies in all study participants.
Genotype count Total
count
Allele frequency HW Chi-
square*
Ala120/
Ala120
Thr120/
Ala120
Thr120/
Thr120
Ala120 Thr120
216 206 45 467 0.68 0.32 0.17
*Chi-square statistic for Hardy-Weinberg (HW) genotype equilibrium; threshold for
significance is Chi-square >5.99 (2 degrees of freedom, and alpha = 0.05).
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TABLE 3 | The association between disease markers and the rs773902 Thr120 allele.
Disease Sample size (disease, control) Odds ratio* (95% CI) p-value**
Microalbuminuria (ACR > 3.5 g/mol) 194, 261 1.18 (0.87–1.6) 0.28
Macroalbuminuria (ACR > 30 g/mol) 78, 377 1.11 (0.77–1.61) 0.56
eGFR < 90 mL/min/1.73 m2 137, 328 0.83 (0.59–1.17) 0.29
Blood positive urine (dipstick result: large, moderate, and small) 165, 289 1.31 (0.98–1.78) 0.073
Leukocyte positive urine (dipstick result: ≥1+) 114, 340 0.8 (0.57–1.13) 0.21
Hypertension (systolic BP>, <140 mmHg) 21, 445 1.48 (0.75–2.89) 0.25
Hypertension (diastolic BP>, <90 mmHg) 26, 440 1.76 (0.98–3.16) 0.057
Random blood glucose (>12.5 mmol/L) 38, 422 0.75 (0.42–1.29) 0.31
Renal disease (CKD, unaffected) 60, 60 1.39 (0.79–2.48) 0.26
CI, Confidence interval; *odds ratio of disease for each extra Thr120 allele. **Threshold for significance after correction for multiple testing is p < 0.0006.
TABLE 4 | The association between disease endophenotypes and the rs773902 Thr120 allele.
Endophenotype Sample Size β value SE (β) Response Ratio* (95% CI) p-value**
ACR 455 0.18 0.14 1.2 (0.92–1.57) 0.18
Systolic blood pressure 466 0.013 0.0083 1.01 (0.996–1.03) 0.13
Diastolic blood pressure 466 0.0066 0.0087 1.01 (0.989–1.03) 0.49
SE, Standard error; CI, Confidence interval; *Response ratio represents the ratio between the ACR or BP of participants for each extra Thr120 allele. **Threshold for
significance after correction for multiple testing is p < 0.017.
the PAR4 rs773902 allele frequency found in the Tiwi is
representative of other Indigenous Australian groups since
many have existed in relative isolation from each other for
several 1000 years.
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